Randomized phase II study of erlotinib (ERL) in two different schedules with concomitant modified XELOX in the first-line treatment of metastatic colorectal cancer (mCRC): corrleation with serial serum levels of amphiregulin (AMR) and transforming growth factor receptor-alpha (TGFa)
Refereed conference paper presented and published in conference proceedings


Full Text

Other information
All Author(s) ListCHAN Anthony Tak Cheung, CHAN Lam Stephen, HO Wing Ming, LAU W., MO Kwok Fai, HUI Edwin P, CHAN Charles M L, POON Annette, RASALKAR Darshana Dattatray, WONG S Cc, TO Ka Fai, KING Ann Dorothy, AHUJA Anil Tejbhan, MA Buig Yue Brigette
Name of ConferenceGastrointestinal Cancers Symposium
Proceedings TitleGastrointestinal Cancers Symposium
Detailed descriptionJ Clin Oncol 2013;31(Suppl 4:425)
Year2013
Pagesabstr 425
LanguagesEnglish-United Kingdom

Last updated on 2018-24-01 at 09:29